Ricerca Biosciences Releases Foresight Similarity Analysis Service
Ricerca Biosciences
, a preclinical contract research organization providing services to the biopharmaceutical industry, has announced its similarity analysis service, Foresight™.
Foresight allows compound assay results to be compared against the assay results of a large reference set of pharmacologically active compounds. The tool helps predict
in vivo
effects from
in vitro
pharmacology data and provides insight into additional, non-obvious compound activities.
The analysis service allows scientists to discover clues to the possibilities of a compound. Foresight can be used to direct compound modification to avoid adverse effects and determine new indications for safe or novel compounds.
Ricerca has previous worked with clients to profile compounds in the discovery space. With the development of this tool, Ricerca can now offer interpretation and predictive analysis of pharmacological data.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
